Robert S. Epstein's most recent trade in Veracyte Inc was a trade of 9,321 Common Stock done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 9,321 | 73,919 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,780 | 22,139 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 Jan 2025 | 20,000 | 64,598 (0%) | 0% | 8.0 | 160,800 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 15,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Robert S. Epstein | Director | Sale of securities on an exchange or to another person at price $ 38.32 per share. | 12 Nov 2024 | 15,000 | 44,598 (0%) | 0% | 38.3 | 574,830 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 12 Nov 2024 | 15,000 | 59,598 (0%) | 0% | 8.0 | 120,600 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,473 | 44,598 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 2,622 | 18,306 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Robert S. Epstein | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.01 per share. | 15 May 2024 | 612 | 15,684 (0%) | 0% | 115.0 | 70,386 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 9,674 | 33,125 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 1,532 | 16,296 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.09 per share. | 24 May 2023 | 7,600 | 14,764 (0%) | 0% | 71.1 | 540,284 | Common Stock |
| Illumina Inc | Robert S. Epstein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 7,600 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Illumina Inc | Robert S. Epstein | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 212.65 per share. | 24 May 2023 | 492 | 7,164 (0%) | 0% | 212.7 | 104,624 | Common Stock |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 14,731 | 23,451 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,720 | 8,720 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,681 | 2,681 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Robert S. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 881 | 6,424 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Robert S. Epstein | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 397.09 per share. | 25 May 2021 | 385 | 5,543 (0%) | 0% | 397.1 | 152,880 | Common Stock |